Children with Down syndrome (DS) and acute lymphoblastic leukaemia (ALL) have poorer survival and more relapses, than non-DS children with ALL, highlighting an urgent need for deeper mechanistic understanding of DS-ALL. Here, using full exome or cancer genestargeted sequencing of 42 ALL samples from 39 DS patients, we uncover driver mutations in RAS, (KRAS and NRAS) recurring to a similar extent (15/42) as JAK2 (12/42) mutations or P2RY8-CRLF2 fusions (14/42). RAS mutations are almost completely mutually exclusive with JAK2 mutations (p=0.016), driving a combined total of two thirds of analysed cases.
Introduction
Acute lymphoblastic leukaemia (ALL) is the commonest cancer-related cause of death in children and young adults, and the most common malignancy of paediatric age 1, 2 . Children with Down's syndrome (DS) have an approximately 10-50-fold higher incidence of leukaemias than children without DS (non-DS), including B cell -progenitor cell ALL (BCP-ALL) and most types of acute myeloid leukaemia (AML) [3] [4] [5] , with myeloid leukaemia of Down syndrome (ML-DS) being recognized as a DS-specific disease 6 . In addition to a constitutional trisomy 21, DS leukaemias show a distinct pattern of acquired genetic changes.
Almost all cases of ML-DS are characterized by in utero acquired typical mutations in the transcription factor GATA1 [7] [8] [9] , and DS-ALL shows increased incidence of mutations in the tyrosine kinase janus kinase 2 (JAK2) [10] [11] [12] , and greater abundance of rearrangements/ mutations at the cytokine receptor-like factor 2 (CRLF2) locus 11, 13 than non-DS-ALL.
Next generation sequencing (NGS) is opening new insights into the mechanisms of
leukaemogenesis and detecting the spectrum of therapeutic targets 14 . Exome and genome sequencing studies of childhood acute leukaemias revealed partially overlapping profiles of driver mutations underlying the unique nature of each leukaemic type. Acute
Megakaryoblastic Leukaemia (AMKL) in children with Down Syndrome were shown to harbour secondary driver mutations in genes of the cohesion complex, epigenetic regulators and signalling pathways which reveals the similarity with the driver mutational profiles in non-DS AML [15] [16] [17] [18] 19, 20, 21 . Given that constitutional trisomy 21 in DS highly predisposes children to most types of leukaemia, and to a characteristic set of mutations that set them apart from non-DS leukaemias (GATA1, CRLF2, JAK2) it remains unclear if the spectra of driver mutations in DS-ALL would be more similar to ML-DS or to non-DS ALL.
The DS-ALL patients have much worse event-free and overall survival rates than non-DS ALL 14 . Leukaemic blasts from ML-DS are far more sensitive to chemotherapeutic agents than cells from non-DS AML, but blasts from DS-ALL do not differ in this sensitivity to non-DS-ALL blasts 22 . Therefore, while in ML-DS the reduced dose chemotherapy has been successfully applied to reduce treatment-related mortality (TRM), this strategy is not recommended for DS-ALL, (apart from only for a small minority of low-risk DS-ALLs 14 ).
This fact is further corroborated by the largest study of its kind on 653 DS-ALL patients, which has shown that poorer survival rates in DS-ALL are only partially due to higher TRM, and are predominantly due to a much higher incidence of relapse than in non-DS ALL children 14 . The worse outcome could partly be explained by the absence (or very rare appearance) of the favourable prognosis-associated genetic lesions in DS (hyperdiploidy and ETV6-RUNX1 fusions) 23 . All this demonstrates an urgent need for further DS-ALL patient sub-stratification, analysis of the full spectrum of acquired mutations, and a deeper understanding of the mechanisms by which they contribute to the evolution of the primary and relapsing leukaemia.
Here we report the detailed driver mutational profiles of 42 ALL samples from 39 DS patients by full exome or cancer genes-targeted sequencing. In three patients, the spectra of driver mutations are compared between the samples at primary diagnosis and the relapse. We discover driver mutations in RAS (KRAS and NRAS) recurring to a similar (or higher) extent Figure 1) . This event represents the most frequent cause of CRLF2 rearrangement in DS-ALL 14 . All studied DS-ALLs, with exception of one T-cell leukaemia In Figure 1 we summarized all point mutations, SCNAs, and P2RY8-CRLF2 fusion events that pass the criteria for putative driver events (Methods). Out of 42 leukaemia samples, (belonging to 39 individuals), only one sample showed no obvious putative driver mutations. 
RAS mutations are as recurrent as JAK2 mutations in DS-ALL
RAS genes of RAS-RTK pathway harboured putative driver mutations in 36% of BCP-ALLs cases uncovering KRAS (9/41) and NRAS (8/41) genes as one of the most important acquired genetic effectors in DS-ALL. Altogether 66% of BCP-ALL tumours had driver mutations in either RAS or JAK2 genes.
RAS and JAK2 mutations are completely mutually exclusive in DS leukaemias
Mutations in JAK2 on one hand, and RAS -on the other hand, were statistically significantly mutually exclusive (p=0.016 using Fisher's exact one sided test). Only one sample (4-14-T1) In the three relapse cases analysed (Figure 3 ), the dominant changes present in both primary tumour and the relapse were neither JAK2 nor RAS mutations, but mutations in classical tumour suppressor genes (CDKN2A), B-lymphocyte differentiation factors (VPREB1), chromatin remodeller family genes (HDAC9, NCOR1), and/or a P2RY8-CRLF2 fusion, indicating that these were most likely the initiating events. The putative driver events in genes of these gene families were detected cumulatively in 93% of cases, with no significant association with either JAK or RAS groups. The data are compatible with the evolutionary chain of events in which these events initiate the clonal expansion, followed by a subsequent formation of mutually excluding JAK2 or RAS mutated sub-clones that "explode" the subclonal proliferation.
Clonal evolution in DS-ALL: RAS-driven sub-clones can replace other drivers in relapse
In two cases where primary and relapsed tumours were available ( 
Comparison of DS-ALL driver profiles to other NGS-analysed leukaemia types
In order to investigate potential similarities between the repertoires of secondary and tertiary events ? This is why in this analysis we excluded these dominant, DS-specific primary events, and focussed on similarities/dissimilarities of the secondary, tertiary and further driver eventprofiles. Remarkably, the secondary/tertiary driver profiles of DS-ALL and ML-DS were more similar to each other, than to most other non-DS ALL or AML types (Supplementary Figure 3) , apart from non-DS near-diploid ALL and non-DS AMKL. There were also subtle differences: genes of the epigenetic modifier gene family were mutated in 62% of DS-ALL, similar to the percentages found in hypodiploid non-DS-ALL 15 , and slightly higher than in
ML-DS

Discussion
Individuals with DS have a paradoxical association with cancer, with a reduced incidence of most solid tumours, but an increased incidence of all types of leukaemia in childhood, due to mechanisms that are only partially understood 24 . The mechanistic paradigms currently explaining DS-ALL leukaemogenesis paint an incomplete picture: CRLF2 overexpression has been seen as the most frequently recurrent event, which then selects for events activating the JAK2 pathway in approximately a third of the CRLF2-rearranged cases, [10] [11] [12] 25 . In western populations, the frequency of CRLF2 rearrangements and/or overexpression ranges around 5-12% in non-DS ALL, and up to 62% in DS-ALL 11, 13, 26 . CRLF2 mutations alone don't generate dominant relapse clones 26 . JAK2 mutations occur in a third of CRLF2 rearranged/overexpressed DS-ALL cases and predispose to high risk and increased relapse incidence in non-DS ALL 11, 13, 26 . In DS-ALL, neither CRLF2 rearrangements nor JAK2 mutations have a prognostic value 14 . The deeper understanding of the mechanisms of leukaemogenesis in DS-ALL remains an urgent need, especially the insights into the nature of molecular changes in relapsing cases, which are still the predominant reason for the poor survival rate in children with DS-ALL 14 .
Our study leads to several new insights: (i) DS-ALL have a large proportion of driver mutations in KRAS and NRAS genes that are recurrent to a similar extent as JAK2 mutations, or P2RY8-CRLF2 fusions, (ii) RAS mutations are almost completely mutually exclusive with JAK2 mutations down to the level of individual minor sub-clones.
Remarkably, by retrospective analysis of the recently published exome-sequencing studies of Our data support the scenario (depicted in Figure 4 ) in which these events initiate DS-ALL.
ML-DS
Sub-clones then accumulate mutually excluding mutations in either the JAK2 gene or the KRAS and NRAS genes. RAS mutations in many cases seem to appear in later sub-clones, or in relapses, accompanied by the complete disappearance of JAK2 mutations and a gain of extra copies of chr21, but all the while retaining the initiating events.
Our findings on mutual exclusiveness of JAK2 and RAS mutations are concordant with the previous observations, where either JAK or RAS mutations were found dominating in different subtypes of childhood B-precursor ALL 27 .
Our results put a particular spotlight on KRAS mutations, finding them in 21% of DS-ALL (compared to 0%, 2.9%, 9.1%, 18%, and 20% respectively, in different cytogenetic sub-types of non-DS ALL and AML [15] [16] [17] [18] 19, 20 . In paediatric nonDS-ALL with an ETV6-RUNX1 translocation 21 , KRAS mutations were present in 10.5% of cases. KRAS mutations are also prevalent in many solid tissue tumours, and are associated with particularly poor prognosis 28 .
In line with these data we find that majority of KRAS mutated primary DS-ALLs had poor outcome (death or relapse).The activated KRAS protein has also been proven as particularly difficult to counteract by pharmaceutical therapy, and was until recently deemed "undruggable" 29 . The recent development of deltarasin, a compound that disrupts the KRASmembrane association by blocking the farnesylated tail of KRAS binding to PDEδ 14 offers new hope for many KRAS mutated cancers, and among them for probably the most progressive subclonal and relapsed expansions in DS-ALL.
Our data suggest standard chemotherapy managements for DS-ALL could be improved by patient stratification based on mutational profile, potentially considering a more aggressive and modified approach for a fraction of cases with RAS (in particular KRAS) mutations, suggesting the addition of KRAS inhibitors (deltarasin) and /or chromatin modifier-enzyme inhibitors to therapeutic strategies. :21), and the only patient with T-ALL (4-36-T1) had a t(7;11)(P22;Q23).
Figure Legends
Exome sequencing
The overall methodology was as previously described 16, 30 . DNA was extracted from the frozen samples using the QIAamp DNA Mini Kit (Qiagen), exome capture was performed fold. Low VAF mutations were selected if they met the following criteria: at least 2 reads on each strand and minimum 6 reads total, supporting the mutation) (Supplementary Data 4) .
The full lists of coding somatic mutations were retrieved for tumours from the patients for 
CRLF2 analysis
The PAR1 deletions were analysed in ALL samples, using 50ng of genomic DNA, 1U of amplitaq gold (Life Technologies, Paisley, UK) , and primers C1423 and C1445, as 
Statistical analysis
Fisher exact one sided test was used for mutual exclusion of JAK-STAT and MAPK pathways. Somatic mutations from previously published 57 DS-AMKL samples were used in this study for evaluation of driver genes and pathways common between DS-ALL and DS-AMKL 16, 18 . For this analysis DS-AMKL samples were used, and for some comparisons also the advanced TMDs with driver mutations additional to GATA1. 
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